Literature DB >> 18627671

Emerging treatments for Tourette's disorder.

Michael H Bloch1.   

Abstract

Tourette's disorder is a childhood-onset neuropsychiatric disorder characterized by multiple motor and vocal tics. Many children with Tourette's disorder improve throughout adolescence. However, some adults with Tourette's disorder still experience severe symptoms and significant disability. This article examines the evidence base for current treatments for Tourette's disorder. Emerging treatments such as deep brain stimulation, habit reversal therapy, and repetitive trans-cranial magnetic stimulation are also discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627671     DOI: 10.1007/s11920-008-0052-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  49 in total

1.  Effective open-label treatment of tourette's disorder with olanzapine.

Authors:  M Stamenkovic; S D Schindler; H N Aschauer; M De Zwaan; U Willinger; E Resinger; S Kasper
Journal:  Int Clin Psychopharmacol       Date:  2000-01       Impact factor: 1.659

2.  Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial.

Authors:  C Marras; D Andrews; E Sime; A E Lang
Journal:  Neurology       Date:  2001-03-13       Impact factor: 9.910

3.  Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome.

Authors:  Gary R Gaffney; Paul J Perry; Brian C Lund; Kristine A Bever-Stille; Stephan Arndt; Samuel Kuperman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-03       Impact factor: 8.829

4.  Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.

Authors:  J Jankovic; J Orman
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

5.  Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder.

Authors:  F R Sallee; L Nesbitt; C Jackson; L Sine; G Sethuraman
Journal:  Am J Psychiatry       Date:  1997-08       Impact factor: 18.112

6.  Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS).

Authors:  Antonio Mantovani; Sarah H Lisanby; Fulvio Pieraccini; Monica Ulivelli; Paolo Castrogiovanni; Simone Rossi
Journal:  Int J Neuropsychopharmacol       Date:  2005-06-28       Impact factor: 5.176

7.  Tic reduction with pergolide in a randomized controlled trial in children.

Authors:  D L Gilbert; L Dure; G Sethuraman; D Raab; J Lane; F R Sallee
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

8.  Electroconvulsive therapy in a patient with Tourette's syndrome and co-morbid Obsessive Compulsive Disorder.

Authors:  Martin Strassnig; Michael Riedel; Norbert Müller
Journal:  World J Biol Psychiatry       Date:  2004-07       Impact factor: 4.132

9.  Fluphenazine and multifocal tic disorders.

Authors:  C G Goetz; C M Tanner; H L Klawans
Journal:  Arch Neurol       Date:  1984-03
View more
  18 in total

Review 1.  Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?

Authors:  Katharine A Phillips; Dan J Stein; Scott L Rauch; Eric Hollander; Brian A Fallon; Arthur Barsky; Naomi Fineberg; David Mataix-Cols; Ygor Arzeno Ferrão; Sanjaya Saxena; Sabine Wilhelm; Megan M Kelly; Lee Anna Clark; Anthony Pinto; O Joseph Bienvenu; Joanne Farrow; James Leckman
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

2.  Histidine decarboxylase knockout mice, a genetic model of Tourette syndrome, show repetitive grooming after induced fear.

Authors:  Meiyu Xu; Lina Li; Hiroshi Ohtsu; Christopher Pittenger
Journal:  Neurosci Lett       Date:  2015-04-01       Impact factor: 3.046

3.  Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome.

Authors:  Meiyu Xu; Andrew Kobets; Jung-Chieh Du; Jessica Lennington; Lina Li; Mounira Banasr; Ronald S Duman; Flora M Vaccarino; Ralph J DiLeone; Christopher Pittenger
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

4.  Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice.

Authors:  Kyle A Williams; Jean-Dominique Gallezot; Vladimir Pogorelov; Lissandra Castellan Baldan; Maximiliano Rapanelli; Michael Crowley; George M Anderson; Erin Loring; Roxanne Gorczyca; Eileen Billingslea; Suzanne Wasylink; Kaitlyn E Panza; A Gulhan Ercan-Sencicek; Kuakarun Krusong; Bennett L Leventhal; Hiroshi Ohtsu; Michael H Bloch; Zoë A Hughes; John H Krystal; Linda Mayes; Ivan de Araujo; Yu-Shin Ding; Matthew W State; Christopher Pittenger
Journal:  Neuron       Date:  2014-01-08       Impact factor: 17.173

5.  Ablation of fast-spiking interneurons in the dorsal striatum, recapitulating abnormalities seen post-mortem in Tourette syndrome, produces anxiety and elevated grooming.

Authors:  M Xu; L Li; C Pittenger
Journal:  Neuroscience       Date:  2016-03-08       Impact factor: 3.590

6.  Corticostriatal interactions in the generation of tic-like behaviors after local striatal disinhibition.

Authors:  Vladimir Pogorelov; Meiyu Xu; Haleigh R Smith; Gordon F Buchanan; Christopher Pittenger
Journal:  Exp Neurol       Date:  2015-01-15       Impact factor: 5.330

7.  Treatment strategies for tics in Tourette syndrome.

Authors:  Clare M Eddy; Hugh E Rickards; Andrea E Cavanna
Journal:  Ther Adv Neurol Disord       Date:  2011-01       Impact factor: 6.570

Review 8.  Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents.

Authors:  Hannah Weisman; Imraan A Qureshi; James F Leckman; Lawrence Scahill; Michael H Bloch
Journal:  Neurosci Biobehav Rev       Date:  2012-10-23       Impact factor: 8.989

9.  Levetiracetam as an alternative therapy for Tourette syndrome.

Authors:  M A Martínez-Granero; A García-Pérez; F Montañes
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

Review 10.  Clinical course of Tourette syndrome.

Authors:  Michael H Bloch; James F Leckman
Journal:  J Psychosom Res       Date:  2009-12       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.